What is the recommended outpatient antibiotic regimen for preseptal cellulitis?

Outpatient Treatment of Preseptal Cellulitis

For uncomplicated preseptal cellulitis in otherwise healthy patients, prescribe oral cephalexin 500 mg every 6 hours or amoxicillin-clavulanate 875/125 mg twice daily for 5 days, extending only if clinical improvement has not occurred within this timeframe. 1

First-Line Oral Antibiotic Selection

Beta-lactam monotherapy is the standard of care for typical preseptal cellulitis, achieving approximately 96% clinical success because the primary pathogens are Staphylococcus aureus (methicillin-sensitive) and Streptococcus species, particularly Streptococcus pyogenes. 1, 2, 3

Recommended Oral Regimens (Choose One):

• Cephalexin 500 mg orally every 6 hours for 5 days – provides excellent coverage against streptococci and MSSA 1
• Amoxicillin-clavulanate 875/125 mg orally twice daily for 5 days – offers broader coverage including beta-lactamase-producing organisms 1
• Dicloxacillin 250-500 mg orally every 6 hours for 5 days – alternative with comparable streptococcal and MSSA activity 1, 2

Treatment Duration

Treat for exactly 5 days if warmth, tenderness, and periorbital edema are improving and the patient is afebrile; extend treatment only if these symptoms have not improved. 1 High-quality evidence demonstrates that 5-day courses are as effective as 10-day courses for uncomplicated cellulitis. 1

When to Add MRSA Coverage

Routine MRSA coverage is unnecessary for typical preseptal cellulitis. 1 Add MRSA-active antibiotics ONLY when specific risk factors are present:

• Penetrating trauma to the periorbital area 1
• Visible purulent drainage or exudate 1
• Known MRSA colonization or prior MRSA infection 1
• Failure to respond to beta-lactam therapy after 48-72 hours 1
• Systemic inflammatory response syndrome (fever >38°C, tachycardia, hypotension) 1

MRSA-Active Regimens (When Indicated):

• Clindamycin 300-450 mg orally every 6 hours – provides single-agent coverage for both streptococci and MRSA, but use ONLY if local clindamycin resistance is <10% 1, 4, 5
• Trimethoprim-sulfamethoxazole 1-2 double-strength tablets twice daily PLUS a beta-lactam (cephalexin or amoxicillin) – combination required because TMP-SMX lacks reliable streptococcal coverage 1, 4, 5
• Doxycycline 100 mg orally twice daily PLUS a beta-lactam – alternative combination for MRSA coverage 1, 4, 5

Pediatric Dosing

For children with preseptal cellulitis:

• Amoxicillin-clavulanate (weight-based dosing) for 5 days is first-line 6, 7
• Cephalexin 25-50 mg/kg/day divided every 6 hours for 5 days 6
• Clindamycin 10-13 mg/kg/dose every 6-8 hours (maximum 40 mg/kg/day) when MRSA coverage is needed, but only if local resistance <10% 6

Hospitalization Criteria

Admit patients with preseptal cellulitis when any of the following are present:

• Signs suggesting orbital involvement: proptosis, restricted or painful extraocular movements, decreased visual acuity, or afferent pupillary defect 7
• Systemic inflammatory response syndrome (fever, tachycardia, altered mental status) 1, 3
• Age <1 year or inability to tolerate oral medications 7
• Failure of outpatient therapy after 24-48 hours 1
• Concern for intracranial extension or severe complications 3, 7

Inpatient IV Regimens:

• Vancomycin 15-20 mg/kg IV every 8-12 hours for MRSA coverage (A-I evidence) 1, 4, 5
• Cefazolin 1-2 g IV every 8 hours for uncomplicated cases without MRSA risk 1
• Vancomycin PLUS piperacillin-tazobactam 3.375-4.5 g IV every 6 hours for severe infections with systemic toxicity 1

Critical Pitfalls to Avoid

• Do not reflexively add MRSA coverage for typical preseptal cellulitis without specific risk factors—this represents overtreatment and promotes resistance 1
• Do not use doxycycline or TMP-SMX as monotherapy for typical cellulitis because they lack reliable activity against beta-hemolytic streptococci 1
• Do not automatically extend therapy to 7-10 days based on residual erythema alone; extend only if warmth, tenderness, or edema have not improved after 5 days 1
• Do not delay ophthalmology consultation if any signs of orbital involvement develop, as preseptal cellulitis can rapidly progress to orbital cellulitis with vision-threatening complications 7
• Reassess patients within 24-48 hours to verify clinical response, as treatment failure rates of approximately 21% have been reported with some oral regimens 1

Special Considerations

• For immunocompromised patients (including those with malignancy), consider broader initial coverage and lower threshold for hospitalization, as severe complications including toxic shock syndrome can occur 3
• Consider unusual pathogens (such as Proteus species) if the patient fails to respond to standard beta-lactam therapy within 36-48 hours 2
• Sinusitis is a common predisposing factor in over 50% of pediatric cases; address underlying sinus disease to prevent recurrence 7